Back to Search
Start Over
CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both
- Source :
- Clinical pharmacology and therapeutics. 104(2)
- Publication Year :
- 2018
-
Abstract
- Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.
- Subjects :
- Cardiovascular event
Treatment outcome
030204 cardiovascular system & hematology
Pharmacology
Risk Assessment
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Cholesterylester transfer protein
Medicine
Animals
Humans
Pharmacology (medical)
Genetic Predisposition to Disease
030212 general & internal medicine
Dyslipidemias
Hypolipidemic Agents
biology
Cholesterol
business.industry
Cholesterol, HDL
Cetp inhibition
Cholesterol, LDL
Mendelian Randomization Analysis
Cholesterol Ester Transfer Proteins
Clinical trial
Treatment Outcome
chemistry
Cardiovascular Diseases
biology.protein
lipids (amino acids, peptides, and proteins)
business
Biomarkers
Subjects
Details
- ISSN :
- 15326535
- Volume :
- 104
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Clinical pharmacology and therapeutics
- Accession number :
- edsair.doi.dedup.....19b4fa35315bb2124870af2bab25fd55